Emergent BioSolutions Inc. (EBS) Insider Trading

Last 12 months

Insiders sold $1.26M and bought nothing on the open market.

79% of the selling was scheduled in advance under 10b5-1 plans. Director Ronald Richard sold $263k on Dec 5, 2025, 18% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2025.

Net open-market

−$1.26M

0 buys · 11 sales

Under a 10b5-1 plan

79%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

May 2025

May 13, 2025

Get an email when EBS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 7	Donald W Degolyer Director	Sold10b5-1 plan	17,800	$7.09	$126k	14%	Form 4
Oct 1	Paul Anthony Williams SVP, Products Business	Sold10b5-1 plan	3,000	$6.53	$20k	1.9%	Form 4
Jul 1	Paul Anthony Williams SVP, Products Business	Sold10b5-1 plan	3,000	$8.40	$25k	1.9%	Form 4
May 1	Kathryn C Zoon Director	Sold10b5-1 plan 2 parts	17,202	$8.40 average	$144k	18%	Form 4
May 1	Donald W Degolyer Director	Sold10b5-1 plan 2 parts	15,481	$8.40 average	$130k	11%	Form 4
May 1	Sujata Tyagi Dayal Director	Sold10b5-1 plan 2 parts	13,761	$8.40 average	$116k	12%	Form 4
Apr 30	Keith Katkin Director	Sold10b5-1 plan	15,481	$8.28	$128k	14%	Form 4
Apr 1	Paul Anthony Williams SVP, Products Business	Sold10b5-1 plan	4,000	$8.44	$34k	6.0%	Form 4
Dec 5, 2025	Ronald Richard Director	SoldNo plan 2 parts	21,984	$11.97 average	$263k	18%	Form 4
Nov 10, 2025	Donald W Degolyer Director	Sold10b5-1 plan	17,801	$10.54	$188k	13%	Form 4
Nov 7, 2025	Sujata Tyagi Dayal Director	Sold10b5-1 plan	8,552	$10.00	$86k	8.8%	Form 4
Oct 7, 2025	Coleen Glessner EVP, Quality & Ethics, and CPL	Sold10b5-1 plan	30,608	$10.00	$306k	17%	Form 4
Aug 15, 2025	Kathryn C Zoon Director	Sold10b5-1 plan	7,086	$8.87	$63k	9.0%	Form 4
Aug 12, 2025	Donald W Degolyer Director	SoldNo plan	7,844	$8.65	$68k	5.4%	Form 4
May 23, 2025	Keith Katkin Director	Sold10b5-1 plan	7,844	$6.30	$49k	8.3%	Form 4
May 13, 2025	Joseph C Papa President and CEO	Bought	60,000	$5.83	$350k	21%	Form 4
Mar 12, 2025	Neal Franklin Fowler Director	SoldNo plan	35,000	$5.83	$204k	26%	Form 4
Mar 12, 2025	Kathryn C Zoon Director	SoldNo plan	10,000	$5.73	$57k	18%	Form 4
Nov 12, 2024	Donald W Degolyer Director	SoldNo plan	25,000	$10.91	$273k	18%	Form 4
Nov 11, 2024	Marvin L White Director	SoldNo plan	14,287	$11.97	$171k	21%	Form 4

Oct 710b5-1 plan
Donald W Degolyer
Director · sold 17,800 at $7.09
$126k
14% of stake
Oct 110b5-1 plan
Paul Anthony Williams
SVP, Products Business · sold 3,000 at $6.53
$20k
1.9% of stake
Jul 110b5-1 plan
Paul Anthony Williams
SVP, Products Business · sold 3,000 at $8.40
$25k
1.9% of stake
May 110b5-1 plan
Kathryn C Zoon
Director · sold 17,202 at avg $8.40
$144k
18% of stake
May 110b5-1 plan
Donald W Degolyer
Director · sold 15,481 at avg $8.40
$130k
11% of stake
May 110b5-1 plan
Sujata Tyagi Dayal
Director · sold 13,761 at avg $8.40
$116k
12% of stake
Apr 3010b5-1 plan
Keith Katkin
Director · sold 15,481 at $8.28
$128k
14% of stake
Apr 110b5-1 plan
Paul Anthony Williams
SVP, Products Business · sold 4,000 at $8.44
$34k
6.0% of stake
Dec 5, 2025No plan
Ronald Richard
Director · sold 21,984 at avg $11.97
$263k
18% of stake
Nov 10, 202510b5-1 plan
Donald W Degolyer
Director · sold 17,801 at $10.54
$188k
13% of stake
Nov 7, 202510b5-1 plan
Sujata Tyagi Dayal
Director · sold 8,552 at $10.00
$86k
8.8% of stake
Oct 7, 202510b5-1 plan
Coleen Glessner
EVP, Quality & Ethics, and CPL · sold 30,608 at $10.00
$306k
17% of stake
Aug 15, 202510b5-1 plan
Kathryn C Zoon
Director · sold 7,086 at $8.87
$63k
9.0% of stake
Aug 12, 2025No plan
Donald W Degolyer
Director · sold 7,844 at $8.65
$68k
5.4% of stake
May 23, 202510b5-1 plan
Keith Katkin
Director · sold 7,844 at $6.30
$49k
8.3% of stake
May 13, 2025
Joseph C Papa
President and CEO · bought 60,000 at $5.83
$350k
21% of stake
Mar 12, 2025No plan
Neal Franklin Fowler
Director · sold 35,000 at $5.83
$204k
26% of stake
Mar 12, 2025No plan
Kathryn C Zoon
Director · sold 10,000 at $5.73
$57k
18% of stake
Nov 12, 2024No plan
Donald W Degolyer
Director · sold 25,000 at $10.91
$273k
18% of stake
Nov 11, 2024No plan
Marvin L White
Director · sold 14,287 at $11.97
$171k
21% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch EBS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

AXSMAxsome Therapeutics, Inc.

KNSAKiniksa Pharmaceuticals International, plc

PCRXPacira BioSciences Inc.

TGTXTG Therapeutics, Inc.

COLLCollegium Pharmaceutical Inc.

AMPHAmphastar Pharmaceuticals Inc.

RAREUltragenyx Pharmaceutical Inc.

BBIOBridgeBio Pharma, Inc.

Spot a number that looks wrong? Check it in EBS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EBS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.